Doctors are learning more about the wider effects of the injections, from lowering blood pressure to helping people quit ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

Men, especially, were less likely to agree with medical necessity and more likely to stress the role of personal ...

When it comes to oral semaglutide, the OASIS-1 trial showed that it led to a 15.1% reduction in body weight. But this was at ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

A “game-changing” Ozempic-style daily pill could transform public health in Britain, experts have said. The drug is expected ...

Gavin Newsom’s administration has reported that half of the doubling in Medi-Cal costs over the past six years has been from ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & ...